Shahram Jacobs, MD
Internal Medicine · Encino, CANPI 1659439040
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Amgen at 54.9% of the total. 2025 is the largest year on record at $3,006, more than ten times the $247 reported in 2019. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $171.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- AbbVie$198
- Novartis$125
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$69
- Philips North America LLC$37
- plus $243 from 12 others
Across 351 payments — averaging $19,251 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$2.2M
- E.r. Squibb & Sons, L.L.C.$1.2M
- Amgen$927K
- AbbVie$762K
- Eli Lilly$707K
- Taro Pharmaceuticals USA, Inc.$385K
- plus $584K from 7 others
What the payments were for
- Speaking & faculty fees$4,24154%
- Travel & lodging$2,30229%
- Food & beverage$1,35117%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $4,331 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $2,891 |
| AbbVie | 4 | $198 |
| Novartis | 2 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $69 |
| Philips North America LLC | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Vertiflex, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Medicure Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,895 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 14 | $14,350 |
| Repatha SureclickEvolocumab | 11 | $6,074 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $960 |
| Atorvastatin Calcium | 57 | $791 |
| Levothyroxine Sodium | 77 | $723 |
| Liothyronine Sodium | 11 | $712 |
| Metformin Hcl | 46 | $443 |
| Rosuvastatin Calcium | 29 | $398 |
| Gabapentin | 25 | $362 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 16 | $341 |
| Amlodipine Besylate | 39 | $262 |
| Terazosin Hcl | 19 | $187 |
| Clonazepam | 12 | $181 |
| Lisinopril | 22 | $175 |
| Simvastatin | 23 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $25 | $14,35014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Encino
- David KayneEncino$843K
- Jasmin JavaherianEncino$327K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.